Galectin Therapeutics Inc Unit Cons of 2 shs + 1 Wt
(NASDAQ : GALTU)

( )
GALTU PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading GALTU News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.28%72.671.2%$696.83m
CELGCelgene Corporation
-4.70%111.871.3%$645.43m
AMGNAmgen Inc.
-3.40%140.171.0%$605.61m
BIIBBiogen Inc.
-2.33%284.381.2%$526.97m
REGNRegeneron Pharmaceuticals, Inc.
-2.85%358.453.6%$382.78m
ALXNAlexion Pharmaceuticals, Inc.
0.73%125.071.9%$363.71m
ILMNIllumina, Inc.
-3.51%121.963.0%$177.14m
VRTXVertex Pharmaceuticals Incorporated
-3.11%75.692.9%$164.83m
INCYIncyte Corporation
-3.79%103.152.4%$161.54m
TSROTESARO, Inc.
-2.60%136.2417.1%$156.34m
IONSIonis Pharmaceuticals, Inc.
-3.52%45.7810.0%$147.58m
EXELExelixis, Inc.
-9.21%16.576.4%$116.16m
BMRNBioMarin Pharmaceutical Inc.
-1.84%81.474.5%$114.14m
BLUEBluebird Bio, Inc.
-9.44%71.5023.3%$112.20m
AAgilent Technologies, Inc.
-0.07%44.811.6%$111.54m

Company Profile

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.